INDIA: The sudden spike in Covid cases led to an alarming call for every country. In the meantime, India has geared up to counter-fight the deadliest disease.
Bharat Biotech is now available Covid vaccine on CoWIN App
An intranasal Covid vaccine by Bharat Biotech was made available for everyone on the CoWIN App from Friday (December 23, 2022). As per sources, this nasal vaccine can be used as a booster dose.
During this critical time pandemic, China is suffering from a loss of lives shortage of resources as well as medical amenities. The Indian government has already buckled up for backup oxygen plants, ventilators, logistics and Human Resources in case of emergency.
Bharat Biotech previously created Covaxin with public-private collaboration. It is a partnership between Bharat Biotech and the Department of Biotechnology (DBT), and its public-sector partner, the Biotechnology Industry Research Assistance Council (BIRAC).
Regarding the recently released intranasal vaccine, known by the brand name iNCOVACC, Bharat Biotech claims that it is the first intranasal vaccination ever to be approved by Covid for the primary 2-dose schedule and heterologous booster dosage.
Meanwhile, iNCOVACC, in its statement, said, “iNCOVACC had previously been given the go-ahead for the principal 2-dose regimen under Restricted Use in Emergency Situation for Ages 18 and Above. At 14 trial locations across India, phase III studies were carried out for immunogenicity and safety in almost 3100 patients.”
“875 participants participated in heterologous booster dose tests for safety and immunogenicity, with the BBV154 intranasal vaccination given after 2 doses of the two routinely provided COVID-19 vaccines. 9 trial locations were used for the tests throughout India,” according to the statement.
According to reports, Bharat Biotech has established a large manufacturing hub at multiple sites across India, including in Gujarat, Karnataka, Maharashtra and Telangana.
Also Read: Plasma Therapy: A Safe and Effective Treatment for COVID-19
